{"id":493169,"date":"2024-06-04T08:33:14","date_gmt":"2024-06-04T08:33:14","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/493169\/chimeric-antigen-receptor-tcell-therapy-pipeline-insights-2024-updates-clinical-trials-latest-approvals-competitive-landscape-companies-abbvie-abclon-actinium-pharmaceuticals-adagene.html"},"modified":"2024-06-04T08:33:14","modified_gmt":"2024-06-04T08:33:14","slug":"chimeric-antigen-receptor-tcell-therapy-pipeline-insights-2024-updates-clinical-trials-latest-approvals-competitive-landscape-companies-abbvie-abclon-actinium-pharmaceuticals-adagene","status":"publish","type":"post","link":"https:\/\/www.oklahomanews-online.com\/news\/story\/493169\/chimeric-antigen-receptor-tcell-therapy-pipeline-insights-2024-updates-clinical-trials-latest-approvals-competitive-landscape-companies-abbvie-abclon-actinium-pharmaceuticals-adagene.html","title":{"rendered":"Chimeric Antigen Receptor T-cell Therapy Pipeline Insights 2024 Updates | Clinical Trials, Latest Approvals, Competitive Landscape, Companies | AbbVie, AbCLon, Actinium Pharmaceuticals, Adagene"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\">\n<div><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/uploads\/1717393274.jpeg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chimeric Antigen Receptor T-cell Therapy Pipeline Insights 2024 Updates | Clinical Trials, Latest Approvals, Competitive Landscape, Companies | AbbVie, AbCLon, Actinium Pharmaceuticals, Adagene\" src=\"https:\/\/www.abnewswire.com\/uploads\/1717393274.jpeg\" alt=\"Chimeric Antigen Receptor T-cell Therapy Pipeline Insights 2024 Updates | Clinical Trials, Latest Approvals, Competitive Landscape, Companies | AbbVie, AbCLon, Actinium Pharmaceuticals, Adagene\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px;border:0 solid !important\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>CAR T-cell Therapy Pipeline Insights 2024<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic;padding:8px 0px\">As per DelveInsight\u2019s assessment, globally, about 120+ key pharma and biotech companies are working on 460+ pipeline drugs in the Chimeric Antigen Receptor (CAR) T-Cell Therapy landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify\">&ldquo;<a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/report-store\/cart-cell-therapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Chimeric Antigen Receptor (CAR) T-Cell Therapy Pipeline Insight, 2024<\/strong><\/a>&Prime; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the CAR T-cell Therapy Market.<\/p>\n<p style=\"text-align: justify\">The CAR T-cell Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify\"><strong>Chimeric Antigen Receptor (CAR) T-Cell Therapy&nbsp;Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>The report provides insights into:<\/strong>&nbsp;<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">The report provides detailed insights into the&nbsp;<strong>emerging CAR T-cell Therapy in the Market<\/strong>&nbsp;and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li>\n<p>It accesses the different CAR T-cell Therapy therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.<\/p>\n<\/li>\n<li>\n<p>It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li>\n<p>It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the&nbsp;<strong>CAR T-cell Therapy Market.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><em>The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/em><\/p>\n<p style=\"text-align: justify\"><strong>Analysis of Emerging Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>The report covers the emerging products under different phases of clinical development like &ndash;<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Late-stage products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid-stage products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early-stage product (Phase I)&nbsp;<\/p>\n<\/li>\n<li>\n<p>Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li>\n<p>Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>CAR-T pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Intravenous<\/p>\n<\/li>\n<li>\n<p>Intramuscular<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Intratumoral<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Mechanism of Action<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Products have been categorized under various Mechanisms of Action, such as<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>T lymphocyte replacements<\/p>\n<\/li>\n<li>\n<p>Immunologic cytotoxicity<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Learn How the Ongoing Clinical &amp; Commercial Activities will Affect the CAR T-cell Therapy Therapeutic Segment @&nbsp;<\/strong><a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cart-cell-therapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/cart-cell-therapy-competitive-landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/report-store\/cart-cell-therapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Chimeric Antigen Receptor (CAR) T-Cell TherapyTherapeutics Landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify\">There are approx.&nbsp;<strong>120+ key companies<\/strong>&nbsp;which are developing Chimeric Antigen Receptor (CAR) T-Cell Therapy. Currently,<strong>&nbsp;JW Therapeutics<\/strong>&nbsp;is leading the therapeutics market with its CAR-T drug candidates in the most advanced stage of clinical development.<\/p>\n<p style=\"text-align: justify\"><strong>The Leading Players in the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Include:<\/strong><\/p>\n<p style=\"text-align: justify\">AbbVie, AbCLon, Actinium Pharmaceuticals, Adagene, Adicet Bio, AffyImmune Therapeutics, AgenTus Therapeutics, Allife Medical Science and Technology, Allogene Therapeutics, Amgen\/Kite Pharma, Anixa Biosciences, Apceth Biopharma, Arbele Limited, Arcellx Inc, Atara Biotherapeutics, Atossa Therapeutics, Atreca\/Xenor, Aurora Biopharma, Autolus Limited, Beam Therapeutics, Beijing Biohealthcare Biotechnology, Beijing Biohealthcare Biotechnology, Beijing Doing Biomedical, Beijing Immunochina Medical Science and Technology, Beijing Mario Biotech, Bellicum Pharmaceuticals, Benitec Biopharma Limited, Bioatla, Bioceltech Therapeutics, BioNTech, Biosceptre, Bluebird Bio, BrightPath Therapeutics, Bristol-Myers Squibb, Caribou Biosciences, Carina Biotech, CARsgen, Carsgen Therapeutics, Cartesian Therapeutics, Cartherics, CASI Pharmaceuticals\/Juventas Cell Therapy, Celgene, Cellectis, Cellular Biomedicine Group, Celyad Oncology SA, Chimeric Therapeutics, Chongqing Precision Biotechnology Co., Ltd., Cogent Biosciences, Creative Biolabs, CRISPR Therapeutics, Curocell, Elpis Biopharmaceuticals, Endocyte, Enlivex Therapeutics Ltd, Eureka Therapeutics, Eutilex\/Utilities, Exuma, FastBack Bio, Fate Therapeutics, Formula Pharmaceuticals, Fujifilm Holdings Corporation, Fundamenta Therapeutics, GC Cell, Genus oncology, Gilead Sciences, GlaxoSmithKline, Glycotype, Gracell Biotechnology, Grand Vista Biotechnology, Guangdong Zhaotai InVivo Biomedicine Co. Ltd., Guangzhou Bio-gene Technology, Hebei Senlang Biotechnology Inc., Ltd., Helix BioPharma, Helocyte, Hemalogix, Henan Hualong Biotechnology, HRAIN Biotechnology, Humorigin, Hunan Zhaotai Yongren Medical Innovation, iCarTAB BioMed, iCell Gene Therapeutics, Immune Therapeutics, Immuneel, Immunicum, IN8Bio, InnoBation, Innovative Cellular Therapeutics, Innovent Biologics, Intellia Therapeutics, Janssen Pharmaceuticals, JW Therapeutics, KAEDI, Kecellitics Biotech Company Ltd, Kiromic BioPharma, Kite Pharma, Kuur Therapeutics, Liminatus Pharma, Luminary Therapeutics, Maxcyte, Medisix Therapeutics, Miltenyi Biotec, Minerva Biotechnologies, MolMed, Mustang Bio, Nanjing KAEDI Biotech, Noile-Immune Biotech, Novartis Pharmaceuticals, Obsidian Therapeutics, Oncternal Therapeutics, Orgenesis, Oxford Biomedica, Pepromene bio, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Poseida Therapeutics, Precigen, Precision BioSciences, Pregene (ShenZhen) Biotechnology Company, Protheragen, PTX Therapeutics, REGENERON, Sana Biotechnology, Sangamo, Senlang Bio, Sensei Biotherapeutics, Servier, Shanghai Biomed-union Biotechnology, Shanghai GeneChem Co., Ltd., Shanghai Longyao Biotechnology, Shanghai Unicar-Therapy Bio-medicine Technology, Shenzhen BinDeBio, Sinobioway Cell Therapy Co., Ltd., Sorrento Therapeutics, SymVivo, Synthekine, Takeda \/ Noile-Immune Biotech, Targazyme, TC BioPharm, Tessa Therapeutics Ltd., The Beijing Pregene Science and Technology Company, Tianjin Mycure Medical Technology, TILT Biotherapeutics, Timmune Biotech, Tmunity Therapeutics, ToolGen, TrakCel, Transgene, UWELL Biopharma, VCANBIO Cell &amp; Gene Engineering Corporation, Ltd, VorBio, Wellington Zhaotai Therapies, WindMIL Therapeutics, Wugen, Wuhan Bio-Raid Biotechnology, Wuhan Sian Medical Technology, Xi&rsquo;An Yufan Biotechnology, Xyphos Biosciences, Yake Biotechnology, Ziopharm Oncology Inc. Intrexon, and many others.<\/p>\n<p style=\"text-align: justify\"><strong>Chimeric Antigen Receptor (CAR) T-Cell Therapy Emerging and Marketed Drugs Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>CD19-targeted CAR-T cells: Sinobioway Cell Therapy<\/p>\n<\/li>\n<li>\n<p>CEA CAR T: Sorrento Therapeutics<\/p>\n<\/li>\n<li>\n<p>CT 103A: Innovent Biologics<\/p>\n<\/li>\n<li>\n<p>CTL119: Novartis<\/p>\n<\/li>\n<li>\n<p>Descartes-11: Cartesian Therapeutics<\/p>\n<\/li>\n<li>\n<p>EPCAM-targeted CAR T-cells: Sinobioway Cell Therapy<\/p>\n<\/li>\n<li>\n<p>JWCAR029: JW Therapeutics<\/p>\n<\/li>\n<li>\n<p>MB-CART2019.1: Miltenyi Biomedicine<\/p>\n<\/li>\n<li>\n<p>TT11: Tessa Therapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">And Many More<\/p>\n<p style=\"text-align: justify\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @&nbsp;<\/strong><a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cart-cell-therapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/cart-cell-therapy-competitive-landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify\">1. Report Introduction<\/p>\n<p style=\"text-align: justify\">2. Executive Summary<\/p>\n<p style=\"text-align: justify\">3. CAR T-cell Therapy Current Treatment Patterns<\/p>\n<p style=\"text-align: justify\">4. CAR T-cell Therapy &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify\">6. CAR T-cell Therapy Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify\">7. CAR T-cell Therapy Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify\">8. CAR T-cell Therapy Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify\">10. Inactive Products<\/p>\n<p style=\"text-align: justify\">11. Dormant Products<\/p>\n<p style=\"text-align: justify\">12. CAR T-cell Therapy Discontinued Products<\/p>\n<p style=\"text-align: justify\">13. CAR T-cell Therapy Product Profiles<\/p>\n<p style=\"text-align: justify\">14. Key Companies in the CAR T-cell Therapy Market<\/p>\n<p style=\"text-align: justify\">15. Key Products in the CAR T-cell Therapy Therapeutics Segment<\/p>\n<p style=\"text-align: justify\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify\">17. CAR T-cell Therapy Unmet Needs<\/p>\n<p style=\"text-align: justify\">18. CAR T-cell Therapy Future Perspectives<\/p>\n<p style=\"text-align: justify\">19. CAR T-cell Therapy Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify\">20. Appendix<\/p>\n<p style=\"text-align: justify\">21. Report Methodology<\/p>\n<p style=\"text-align: justify\"><strong>Download Sample PDF to Explore the Key Offerings of the Report @&nbsp;<\/strong><a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cart-cell-therapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/cart-cell-therapy-competitive-landscape<\/strong><\/a><\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chimeric-antigen-receptor-tcell-therapy-pipeline-insights-2024-updates-clinical-trials-latest-approvals-competitive-landscape-companies-abbvie-abclon-actinium-pharmaceuticals-adagene\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chimeric-antigen-receptor-tcell-therapy-pipeline-insights-2024-updates-clinical-trials-latest-approvals-competitive-landscape-companies-abbvie-abclon-actinium-pharmaceuticals-adagene\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAR T-cell Therapy Pipeline Insights 2024 As per DelveInsight\u2019s assessment, globally, about 120+ key pharma and biotech companies are working on 460+ pipeline drugs in the Chimeric Antigen Receptor (CAR)<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/posts\/493169"}],"collection":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/comments?post=493169"}],"version-history":[{"count":0,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/posts\/493169\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/media?parent=493169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/categories?post=493169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/tags?post=493169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}